ArticleEndoscopic ultrasound
Value of EUS through-the-needle microforceps biopsy sampling in pancreatic cystic lesions: The MOBIDYC trial-A prospective multicenter study (with video).
Article in Endoscopic ultrasound. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Accurate diagnosis of pancreatic cystic lesions (PCLs) is essential, as some have malignant potential while others are benign. EUS through-the-needle biopsy (EUS-TTNB) using Moray microforceps has emerged as a promising technique for obtaining cyst wall histology, though prospective multicenter data are lacking. Methods: We conducted a nationwide, prospective, multicenter study including 93 patients with PCLs ≥20 mm requiring histological diagnosis after initial imaging work-up. The primary outcome was the histological performance of EUS-TTNB. Secondary outcomes included technical success, predictors of histological performance, safety, and concordance with the gold standard. Results: EUS-TTNB provided adequate histological specimens in 72% of cases, with a 100% technical success rate. Predictive factors for histological performance included proximal location of the PCL ( Conclusion: EUS-TTNB is a valuable tool for diagnosing indeterminate PCLs, with superior performance compared with standard techniques. However, given the risk of adverse events, its use should be reserved for selected cases, especially in high-risk surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.